TY - JOUR
T1 - Quinolones for treatment of nosocomial pneumonia
T2 - A meta-analysis
AU - Shorr, Andrew F.
AU - Susla, Gregory B.
AU - Kollef, Marin H.
N1 - Funding Information:
Potential conflicts of interest. A.F.S. and M.H.K. received funding from Ortho-McNeil Pharmaceutical, but no extra funding was provided for the preparation of this analysis. G.B.S.: no conflict.
PY - 2005/2/24
Y1 - 2005/2/24
N2 - Although quinolones are often used to treat nosocomial pneumonia (NP), there have been few trials documenting their efficacy in treating NP. Given the growing use of quinolones and issues regarding resistance, we conducted a meta-analysis of all trials of quinolones for treatment of NP. We identified 5 randomized trials comparing quinolones with other agents used to treat NP. The studies varied in both quality and sample size and included a total of nearly 1200 subjects. Four of the 5 trials used ciprofloxacin, administered every 8 h, whereas the fifth used levofloxacin administered daily. In 3 trials, the comparator agent was imipenem-cilistatin, whereas, in 2 trials, ceftazadime was the comparator agent. The efficacy of quinolones and comparator antibiotics was similar, with a pooled odds ratio for clinical cure of 1.12 (95% confidence interval, 0.80-1.55). Neither microbiological eradication rates nor mortality rates varied on the basis of antimicrobial selection.
AB - Although quinolones are often used to treat nosocomial pneumonia (NP), there have been few trials documenting their efficacy in treating NP. Given the growing use of quinolones and issues regarding resistance, we conducted a meta-analysis of all trials of quinolones for treatment of NP. We identified 5 randomized trials comparing quinolones with other agents used to treat NP. The studies varied in both quality and sample size and included a total of nearly 1200 subjects. Four of the 5 trials used ciprofloxacin, administered every 8 h, whereas the fifth used levofloxacin administered daily. In 3 trials, the comparator agent was imipenem-cilistatin, whereas, in 2 trials, ceftazadime was the comparator agent. The efficacy of quinolones and comparator antibiotics was similar, with a pooled odds ratio for clinical cure of 1.12 (95% confidence interval, 0.80-1.55). Neither microbiological eradication rates nor mortality rates varied on the basis of antimicrobial selection.
UR - http://www.scopus.com/inward/record.url?scp=13944261537&partnerID=8YFLogxK
U2 - 10.1086/426191
DO - 10.1086/426191
M3 - Article
C2 - 15712099
AN - SCOPUS:13944261537
VL - 40
SP - S115-S122
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - SUPPL.
ER -